TNDM · Tandem Diabetes Care Inc

Track TNDM — free

$16.52 +0.02 (+0.12%) At close · Oct 5

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$1.09B

69.58M

Volume · Oct 5 1.79M Avg daily vol (3M) 1.97M

Up next

Next earnings call

Nov 5, 2026 Scheduled · in 4 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$1.04B

Trailing 12 months

Net income (TTM)

−$63.31M

Trailing 12 months

Revenue growth YoY

+5.8%

Year over year

Operating margin

-4.4%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-2.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.9%

Year over year · more shares

Price change (1Y)

+25.9%

Trailing year

Short interest

17.9%

Latest settlement · 7.9 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −15%

below

Price vs 50-day avg −15%

below

RSI (14) 40

neutral

MACD trend Positive

52-week position 24%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −17%

trailing

6-month return −22%

trailing

YTD return −25%

this year

Relative strength −33%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $20 › 200d $19 — 50d above 200d

Institutional flow Accumulating

3 of 275 funds reported for Sep 30 · net +783 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

17.93% of float · ▲ +6.1% MoM · 7.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

275 holders — mid 3-yr range

Squeeze score 67

elevated · 0–100

Fundamentals

Weak

Revenue growth +8%

Y/Y

Gross margin 54%

expanding

EPS growth −107%

Y/Y

Free cash flow $-29.7M

Balance sheet $69.0M

net debt

Quant / Vol

risk profile

Very High

Volatility 77%

annualized · 1-yr

Max drawdown −55%

past year

ATR 6.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 3

Latest guidance · from the 8-K filed Aug 6, 2026

Sales · For the year ending December 31, 2026 Initiated $1.07B – $1.09B

prior FY $1.01B midpoint +5.9% Y/Y

U.S. sales · For the year ending December 31, 2026 Initiated $730M – $745M

International sales · For the year ending December 31, 2026 Initiated $335M – $340M

Gross margin · For the year ending December 31, 2026 Initiated 56% – 57%

Adjusted EBITDA margin · For the year ending December 31, 2026 Non-GAAP Initiated 5% – 6%

Non-cash charges included in cost of goods sold and operating ex · For the year ending December 31, 2026 Initiated $85M

Non-cash, stock-based compensation expense · For the year ending December 31, 2026 Initiated $65M

Depreciation and amortization expense · For the year ending December 31, 2026 Initiated $20M

Guided vs delivered · last 3 settled

Worldwide sales full year 2021

guided $685M – $695M

guided $685M – $695M $702.8M Beat +1.9%

Worldwide sales full year of 2020

guided $465M – $475M

guided $465M – $475M $498.83M Beat +6.1%

Worldwide sales the second quarter

guided at least $85M

guided at least $85M $109.24M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−15% Bearish

Price vs 50-day avg

−15% Bearish

RSI (14)

40 Neutral

MACD trend

Positive Bullish

52-week position

24% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $20 › 200d $19 — 50d above 200d

Institutional flow Accumulating

3 of 275 funds reported for Sep 30 · net +783 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

17.93% of float · ▲ +6.1% MoM · 7.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

275 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $13 Now $17 · 24% Range high $28

vs 200-day avg -15% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$9.15M	Six Months Ended June 30, 2026	—
Adjusted EBITDA margin non-GAAP	2%	Six Months Ended June 30, 2026	—
Direct sales to customers as a percentage of international sales	13%	the three months ended June 30, 2026 filing	—
International pump shipments	11,000	the three months ended June 30, 2026 filing	+22.2%

Non-GAAP free cash flow non-GAAP	-$33.89M	Six Months Ended June 30, 2026	—
Non-GAAP net loss non-GAAP	-$41.56M	Six Months Ended June 30, 2026	—
Non-GAAP operating loss non-GAAP	-$31.23M	Six Months Ended June 30, 2026	—
Non-GAAP operating margin non-GAAP	-6%	Six Months Ended June 30, 2026	—
Pump shipments	33,000	second quarter 2026	+266.7%

Pump shipments in the United States	22,000	second quarter 2026	+4.8%

pumps shipped worldwide	33,000	the three months ended June 30, 2026 filing	—
Sales through the pharmacy channel as a percentage of United States sales	10%	second quarter 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TNDM Tandem Diabetes Care Inc this stock	$1.09B	-24.8%	+7.9%	—	17.9%
ABT Abbott Laboratories	$174.90B	-20.1%	+5.7%	28.1	1.1%
MDT Medtronic plc	$113.38B	-8.4%	+8.4%	21.8	1.3%
SYK Stryker Corp	$104.47B	-18.8%	+11.2%	28.2	2.0%
BSX Boston Scientific Corp	$63.59B	-55.5%	+12.5%	17.8	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

275

% held: 122.2%
Reported: 3 of 275
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

236

View

Short & Settlement

Short Interest Rising

Shares short

12.5M

Days to cover: 7.9d
Change: +720.6K sh

View

Short Volume

Short vol %

61%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

2.4K

Value: $47.0K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

44.5%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: Mar 3, 2026

View

Financials

Revenue (FY)

$1.0B

Net income (FY): $-204.7M
EPS diluted: $-3.04

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 11, 2026
This year: 12

View

Proposed Sales

Value

$6.3K

Shares: 360
Filed: Sep 17, 2026

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 5, 2026

Last webcast: Aug 11, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
TNDM	+0.6%	-17.0%	-21.7%	+1.3%	-24.8%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-0.6%	-17.6%	-33.3%	-0.3%	-38.5%

Key facts CIK 1438133 CUSIP 875372203 13F (30d) 15 filings 9 filers Visit website Investor relations

TNDM · Tandem Diabetes Care Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance